Home
    • Plans Blog Contact
    Pyxis Oncology Inc logo

    Pyxis Oncology Inc

    PYXS
    Last price US$3.00
    Market cap US$189.1m
    12M price change 165.53%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Syneos HealthSYNH Industry peer Pluri IncPLUR Industry peer Prenetics Global LtdPRE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Pyxis Oncology Inc Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical tria Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Pyxis Oncology Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 13, 2026

    Quarterly result summary

    Net loss was -$25.3M. R&D expense was $16.1M.

    Net loss -$25.3M reported
    R&D expense $16.1M reported
    G&A expense $9.9M reported
    Cash $34.5M reported

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    We expect to report updated monotherapy data in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) this fall, followed by updated first-line combination data with pembrolizumab in the fourth quarter.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 13, 2026 SEC filing 8-K Aug 13, 2026 SEC filing 10-Q May 14, 2026 SEC filing 8-K May 14, 2026 Earnings release Earnings release May 14, 2026 Earnings release Earnings release Mar 23, 2026 SEC filing 10-K Mar 23, 2026 SEC filing 8-K Mar 23, 2026 Earnings material Earnings release Mar 23, 2026 SEC filing 10-Q Nov 03, 2025 SEC filing 8-K Nov 03, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    Pyxis Oncology Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Return on Equity

    Score 0.08/5
    Pyxis Oncology Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Pyxis Oncolo... PYXS US$189.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.93/5
    Pyxis Oncology Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Pyxis Oncolo... PYXS US$189.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Leverage

    Score 3.09/5
    Pyxis Oncology Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Pyxis Oncolo... PYXS US$189.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Pyxis Oncology Inc logo

    Pyxis Oncology Inc

    US$3.00

    US$189.1m

    -18.35%

    165.53%